Cover Image
Market Research Report

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Pipeline Review, H1 2018

Published by Global Markets Direct Product code 556451
Published Content info 50 Pages
Immediate Delivery Available
Price
Back to Top
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Pipeline Review, H1 2018
Published: March 27, 2018 Content info: 50 Pages
Description

Summary:

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2018'; Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 3 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Sedation, General Anesthetic Effect, Insomnia, Anesthetic Effect, Hypertension and Status Epilepticus.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
  • The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1388TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit Gamma 2 or GABRG2) - Overview
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Paion AG
  • Primex Pharmaceuticals Oy
  • Shire Plc
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles
  • clonazepam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EL-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LASSBio-785 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LASSBio-786 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • midazolam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • midazolam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Dormant Products
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Discontinued Products
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit Gamma 2 or GABRG2) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 15, 2018: European Medicines Agency: Defect with Buccolam oral syringes
  • Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera
  • Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required
  • Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
  • Jun 05, 2017: Primex Pharmaceuticals at Euroanesthesia 2017: Next Innovation in the Management of Pediatric Sedation
  • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
  • Oct 05, 2016: Primex Files for Marketing Authorization for a pediatric sedative medication
  • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
  • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
  • Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists
  • Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in pediatric anesthesia since propofol
  • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
  • Apr 11, 2016: Paion Successfully Completes Patient Recruitment in Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
  • Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
  • Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent for Remimazolam Besylate
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2018
  • Pipeline by Paion AG, H1 2018
  • Pipeline by Primex Pharmaceuticals Oy, H1 2018
  • Pipeline by Shire Plc, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top